董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ron Williams | 男 | Executive Chairman | 76 | 18.50万美元 | 359.65 | 2025-07-29 |
| William Wulf | 男 | Independent Director | 66 | 27.00万美元 | 70.71 | 2025-07-29 |
| Silvana Battaglia | -- | Independent Director | -- | 25.50万美元 | 7.90 | 2025-07-29 |
| Karen A. McLoughlin | -- | Independent Director | -- | 28.00万美元 | 8.11 | 2025-07-29 |
| Diana L. McKenzie | -- | Independent Director | -- | 27.00万美元 | 6.61 | 2025-07-29 |
| Ravi Sachdev | 男 | Vice Chairman of the Board | 49 | 未披露 | 未持股 | 2025-07-29 |
| Sharad S. Mansukani | 男 | Independent Director | 56 | 26.75万美元 | 191.78 | 2025-07-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ron Williams | 男 | Executive Chairman | 76 | 18.50万美元 | 359.65 | 2025-07-29 |
| Ben Shaker | 男 | Chief Markets Officer, Interim Principal Executive Officer | 43 | 535.75万美元 | 154.24 | 2025-07-29 |
| Girish Venkatachaliah | 男 | Chief Technology Officer | 52 | 205.61万美元 | 57.34 | 2025-07-29 |
| Timothy Gertsch | -- | Chief Accounting Officer | -- | 未披露 | 未持股 | 2025-07-29 |
| Jeffrey A. Schwaneke | -- | Chief Financial Officer, Interim Principal Executive Officer | -- | 561.09万美元 | 60.41 | 2025-07-29 |
| Karthik Rao | -- | Chief Medical Officer | -- | 未披露 | 未持股 | 2025-07-29 |
| Denise Zamore | -- | Chief Legal Officer and Corporate Secretary | -- | 312.34万美元 | 32.97 | 2025-07-29 |
| Heidi Hittner | -- | Executive Vice President and Chief of Staff | -- | 未披露 | 未持股 | 2025-07-29 |
董事简历
中英对照 | 中文 | 英文- Ron Williams
-
Ron Williams自2017年以来一直担任Agilon Health的董事兼董事会主席。Williams先生也是RW2Enterprises的董事长兼首席执行官，并担任CD&R的运营顾问。Williams先生是American Express Company公司、波音公司公司和强生公司公司的董事。Williams先生还于2011年5月至2017年10月担任Envision梦百合的董事会成员。Williams先生分别于2006年2月和2006年10月至2010年12月和2011年4月担任安泰保险金融集团的首席执行官和董事长。Williams先生还担任Conference Board的主席以及NAF和Peterson Institute for International Economics的董事。Williams先生在罗斯福大学（Roosevelt University）获得学士学位，并在麻省理工学院斯隆管理学院（MIT Sloan School of Management）获得管理学硕士学位。
Ron Williams has served as a director and chairman of the board of agilon health since 2017. Mr. Williams also is chairman and CEO of RW2 Enterprises and serves as an operating advisor to CD&R. Mr. Williams serves on the board of directors of American Express Company, The Boeing Company and Johnson & Johnson. Mr. Williams also served on the Board of Envision Healthcare from May 2011 to October 2017. Mr. Williams served as the CEO and Chairman of Aetna Inc. from February 2006 and October 2006 to December 2010 and April 2011 respectively. Mr. Williams also serves as Chairman of The Conference Board and a director of NAF and the Peterson Institute for International Economics. Mr. Williams received his B.A. from Roosevelt University and holds an M.S. in Management from MIT Sloan School of Management. - Ron Williams自2017年以来一直担任Agilon Health的董事兼董事会主席。Williams先生也是RW2Enterprises的董事长兼首席执行官，并担任CD&R的运营顾问。Williams先生是American Express Company公司、波音公司公司和强生公司公司的董事。Williams先生还于2011年5月至2017年10月担任Envision梦百合的董事会成员。Williams先生分别于2006年2月和2006年10月至2010年12月和2011年4月担任安泰保险金融集团的首席执行官和董事长。Williams先生还担任Conference Board的主席以及NAF和Peterson Institute for International Economics的董事。Williams先生在罗斯福大学（Roosevelt University）获得学士学位，并在麻省理工学院斯隆管理学院（MIT Sloan School of Management）获得管理学硕士学位。
- Ron Williams has served as a director and chairman of the board of agilon health since 2017. Mr. Williams also is chairman and CEO of RW2 Enterprises and serves as an operating advisor to CD&R. Mr. Williams serves on the board of directors of American Express Company, The Boeing Company and Johnson & Johnson. Mr. Williams also served on the Board of Envision Healthcare from May 2011 to October 2017. Mr. Williams served as the CEO and Chairman of Aetna Inc. from February 2006 and October 2006 to December 2010 and April 2011 respectively. Mr. Williams also serves as Chairman of The Conference Board and a director of NAF and the Peterson Institute for International Economics. Mr. Williams received his B.A. from Roosevelt University and holds an M.S. in Management from MIT Sloan School of Management.
- William Wulf
-
William Wulf自2017年以来一直担任Agilon Health的董事。除了担任Agilon Health的董事外，Wulf博士还是Central Ohio Primary Care的首席执行官。COPC是我们的医师集团合作伙伴之一。Wulf博士于1996年担任COPC的创始合伙人，并在25年后于2013年担任首席执行官，担任执业内科医生和企业医疗总监。Wulf博士还曾担任多个付款人的顾问，包括Anthem、Aetna和United梦百合。Wulf博士在俄亥俄州立大学（Ohio State University）获得学士学位，在托莱多的俄亥俄医学院（Medical College of Ohio）获得医学博士学位。
William Wulf has served as a director of agilon health since 2017. In addition to his role as director of agilon health, Dr. Wulf is the CEO of Central Ohio Primary Care. COPC is one of physician group partners. Dr. Wulf was a founding partner of COPC in 1996 and assumed the role of CEO in 2013 after 25 years as a practicing Internist and the Corporate Medical Director. Dr. Wulf has also served as an advisor for multiple payors, including Anthem, Aetna and United Healthcare. Dr. Wulf received his B.S. from Ohio State University and his M.D. from the Medical College of Ohio in Toledo. - William Wulf自2017年以来一直担任Agilon Health的董事。除了担任Agilon Health的董事外，Wulf博士还是Central Ohio Primary Care的首席执行官。COPC是我们的医师集团合作伙伴之一。Wulf博士于1996年担任COPC的创始合伙人，并在25年后于2013年担任首席执行官，担任执业内科医生和企业医疗总监。Wulf博士还曾担任多个付款人的顾问，包括Anthem、Aetna和United梦百合。Wulf博士在俄亥俄州立大学（Ohio State University）获得学士学位，在托莱多的俄亥俄医学院（Medical College of Ohio）获得医学博士学位。
- William Wulf has served as a director of agilon health since 2017. In addition to his role as director of agilon health, Dr. Wulf is the CEO of Central Ohio Primary Care. COPC is one of physician group partners. Dr. Wulf was a founding partner of COPC in 1996 and assumed the role of CEO in 2013 after 25 years as a practicing Internist and the Corporate Medical Director. Dr. Wulf has also served as an advisor for multiple payors, including Anthem, Aetna and United Healthcare. Dr. Wulf received his B.S. from Ohio State University and his M.D. from the Medical College of Ohio in Toledo.
- Silvana Battaglia
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Karen A. McLoughlin
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Diana L. McKenzie
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Ravi Sachdev
-
Ravi Sachdev，自2019年8月起担任公司董事，担任提名/公司治理委员会成员，并于2008年9月至2025年3月担任审计委员会成员。自2015年6月起担任私募股权公司Clayton Dubilier & Rice， LLC的合伙人，他专注于医疗保健行业。早些时候，萨赫杰夫曾在几家投资银行工作。2010年11月至2015年6月，他曾担任J.P. Morgan的董事总经理兼医疗保健服务联席主管。在此之前，他曾担任Deutsche Bank Securities， Inc.的董事总经理（2009年1月至2010年11月），德意志银行董事（2007年1月至2009年1月）。在2006年加入Deutsche Bank担任副总裁之前，1998年至2006年，他曾担任Peter J. Solomon Company（一家投资银行精品，专门从事医疗保健行业的并购）的副总裁。Sachdev先生拥有财务和财务分析Steven Madden， Ltd.的知识，以衡量企业绩效。
Ravi Sachdev,has served as a director of the Company as a member of the Nominating/Corporate Governance Committee since August 2019 and as a member of the Audit Committee from September 2008 until March 2025. As a Partner of the private equity firm Clayton Dubilier & Rice, LLC since June 2015, Mr. Sachdev focuses on the healthcare sector. Earlier, Mr. Sachdev worked at several investment banks. He was a Managing Director and Co- Head of Healthcare Services at J.P. Morgan from November 2010 until June 2015 and prior to that held the positions of Managing Director at Deutsche Bank Securities, Inc. from January 2009 until November 2010 and Director at Deutsche Bank from January 2007 until January 2009. Prior to joining Deutsche Bank in 2006 as a Vice President, Mr. Sachdev served as a Vice President at Peter J. Solomon Company, an investment banking boutique, specializing in mergers and acquisitions in the healthcare sector, from 1998 to 2006. Mr. Sachdev possesses knowledge of finance and the financial analytics Steven Madden, Ltd. ed to measure business performance. - Ravi Sachdev，自2019年8月起担任公司董事，担任提名/公司治理委员会成员，并于2008年9月至2025年3月担任审计委员会成员。自2015年6月起担任私募股权公司Clayton Dubilier & Rice， LLC的合伙人，他专注于医疗保健行业。早些时候，萨赫杰夫曾在几家投资银行工作。2010年11月至2015年6月，他曾担任J.P. Morgan的董事总经理兼医疗保健服务联席主管。在此之前，他曾担任Deutsche Bank Securities， Inc.的董事总经理（2009年1月至2010年11月），德意志银行董事（2007年1月至2009年1月）。在2006年加入Deutsche Bank担任副总裁之前，1998年至2006年，他曾担任Peter J. Solomon Company（一家投资银行精品，专门从事医疗保健行业的并购）的副总裁。Sachdev先生拥有财务和财务分析Steven Madden， Ltd.的知识，以衡量企业绩效。
- Ravi Sachdev,has served as a director of the Company as a member of the Nominating/Corporate Governance Committee since August 2019 and as a member of the Audit Committee from September 2008 until March 2025. As a Partner of the private equity firm Clayton Dubilier & Rice, LLC since June 2015, Mr. Sachdev focuses on the healthcare sector. Earlier, Mr. Sachdev worked at several investment banks. He was a Managing Director and Co- Head of Healthcare Services at J.P. Morgan from November 2010 until June 2015 and prior to that held the positions of Managing Director at Deutsche Bank Securities, Inc. from January 2009 until November 2010 and Director at Deutsche Bank from January 2007 until January 2009. Prior to joining Deutsche Bank in 2006 as a Vice President, Mr. Sachdev served as a Vice President at Peter J. Solomon Company, an investment banking boutique, specializing in mergers and acquisitions in the healthcare sector, from 1998 to 2006. Mr. Sachdev possesses knowledge of finance and the financial analytics Steven Madden, Ltd. ed to measure business performance.
- Sharad S. Mansukani
-
Sharad S. Mansukani是Convey Holding Parent, Inc.董事会主席，在TPG收购本公司后，于2019年9月被任命为Convey Holding Parent, Inc.董事会成员。Sharad S. Mansukani是医学博士，他于2013年10月30日被任命为董事，于2007年被任命为SCA的董事。Mansukani博士从2005年开始担任TPG的高级顾问。他担任拉西斯保健公司（IASIS Healthcare Corp.）、Immucor Inc.、IMS Health Holdings, Inc.与Par Pharmaceuticals Companies, Inc.的董事。Mansukani博士担任美国信诺集团（CIGNA）的董事会战略顾问，在这之前，担任HealthSpring Inc.的董事会副主席。Mansukani博士还担任费城儿童医院（Children’s Hospital of Philadelphia）的董事，并担任《美国医疗品质期刊》（American Journal of Medical Quality）、《管理式照护》（Managed Care）、《生物技术医疗保健》（Biotechnology Healthcare）与《美国健康与药物福利》（American Health &Drug Benefits）的编辑委员会委员。Mansukani博士被任命为Medicare的支付顾问和监管委员会委员，在这之前，他担任健保与医疗补助服务中心（Centers for Medicare and Medicaid Services，CMS）的高级顾问，并担任医疗保险制度改革执行委员会（Medicare Reform Executive Committee）的委员。在这之前，Mansukani博士担任宾夕法尼亚大学（University of Pennsylvania）与天普大学医学院（Temple University School of Medicine）的教员。Mansukani博士在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）完成眼科学住院医师实习与研究，并在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）完成了质量管理与管理式照护的研究。
Sharad S. Mansukani is the Chairman of our Board of Directors and was appointed to our Board of Directors in September 2019 following TPG's acquisition of the Company. Dr. Mansukani has served as a Senior Advisor of TPG since 2005. From 2012 to 2015 Dr. Mansukani served as a Strategic Advisor to the board of directors of Cigna Corp. Prior to his work with Cigna Corp., Dr. Mansukani was appointed to Medicare's Program Advisory and Oversight Committee by the Secretary of the Department of Health and Human Services from 2009 to 2012. Dr. Mansukani also served as a Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services CMS from 2003 to 2005 where he advised on design and implementation of the Medicare prescription drug benefit, Medicare Part B reform and Medicare Advantage policy. Prior to his work with CMS, Dr. Mansukani was a Senior Vice President and Chief Medical Officer at Health Partners from 1999 to 2003. Dr. Mansukani currently serves on the board of directors of Agilon Health Solutions, and previously served as the Vice Chairman of the board of directors of Health Spring, Inc. from 2007 to 2012 and as Chairman of the board of directors of Envision Rx Options from 2013 to 2016. Dr. Mansukani also served on the boards of directors of Endo International plc from 2017 to 2019 Kindred Healthcare Inc. from 2015 to 2018 Surgical Care Affiliates, Inc. from 2007 to 2017 IASIS Healthcare from 2005 to 2018 IMS Health Holdings, Inc. from 2009 to 2016 and Par Pharmaceutical Holdings, Inc. from 2012 to 2015 prior to Endo International PLC's acquisition of Par Pharmaceutical Holdings, Inc. in 2015. Dr. Mansukani currently serves on the board of directors of the Children's Hospital of Philadelphia. Dr. Mansukani completed a residency and fellowship in ophthalmology at the University of Pennsylvania School of Medicine and a fellowship in quality management and managed care at the Wharton School of the University of Pennsylvania. Dr. Mansukani is a graduate of the Managed Care Executive Program at the Kellogg School of Business and is board certified in medical management by the American College of Physician Executives. - Sharad S. Mansukani是Convey Holding Parent, Inc.董事会主席，在TPG收购本公司后，于2019年9月被任命为Convey Holding Parent, Inc.董事会成员。Sharad S. Mansukani是医学博士，他于2013年10月30日被任命为董事，于2007年被任命为SCA的董事。Mansukani博士从2005年开始担任TPG的高级顾问。他担任拉西斯保健公司（IASIS Healthcare Corp.）、Immucor Inc.、IMS Health Holdings, Inc.与Par Pharmaceuticals Companies, Inc.的董事。Mansukani博士担任美国信诺集团（CIGNA）的董事会战略顾问，在这之前，担任HealthSpring Inc.的董事会副主席。Mansukani博士还担任费城儿童医院（Children’s Hospital of Philadelphia）的董事，并担任《美国医疗品质期刊》（American Journal of Medical Quality）、《管理式照护》（Managed Care）、《生物技术医疗保健》（Biotechnology Healthcare）与《美国健康与药物福利》（American Health &Drug Benefits）的编辑委员会委员。Mansukani博士被任命为Medicare的支付顾问和监管委员会委员，在这之前，他担任健保与医疗补助服务中心（Centers for Medicare and Medicaid Services，CMS）的高级顾问，并担任医疗保险制度改革执行委员会（Medicare Reform Executive Committee）的委员。在这之前，Mansukani博士担任宾夕法尼亚大学（University of Pennsylvania）与天普大学医学院（Temple University School of Medicine）的教员。Mansukani博士在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）完成眼科学住院医师实习与研究，并在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）完成了质量管理与管理式照护的研究。
- Sharad S. Mansukani is the Chairman of our Board of Directors and was appointed to our Board of Directors in September 2019 following TPG's acquisition of the Company. Dr. Mansukani has served as a Senior Advisor of TPG since 2005. From 2012 to 2015 Dr. Mansukani served as a Strategic Advisor to the board of directors of Cigna Corp. Prior to his work with Cigna Corp., Dr. Mansukani was appointed to Medicare's Program Advisory and Oversight Committee by the Secretary of the Department of Health and Human Services from 2009 to 2012. Dr. Mansukani also served as a Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services CMS from 2003 to 2005 where he advised on design and implementation of the Medicare prescription drug benefit, Medicare Part B reform and Medicare Advantage policy. Prior to his work with CMS, Dr. Mansukani was a Senior Vice President and Chief Medical Officer at Health Partners from 1999 to 2003. Dr. Mansukani currently serves on the board of directors of Agilon Health Solutions, and previously served as the Vice Chairman of the board of directors of Health Spring, Inc. from 2007 to 2012 and as Chairman of the board of directors of Envision Rx Options from 2013 to 2016. Dr. Mansukani also served on the boards of directors of Endo International plc from 2017 to 2019 Kindred Healthcare Inc. from 2015 to 2018 Surgical Care Affiliates, Inc. from 2007 to 2017 IASIS Healthcare from 2005 to 2018 IMS Health Holdings, Inc. from 2009 to 2016 and Par Pharmaceutical Holdings, Inc. from 2012 to 2015 prior to Endo International PLC's acquisition of Par Pharmaceutical Holdings, Inc. in 2015. Dr. Mansukani currently serves on the board of directors of the Children's Hospital of Philadelphia. Dr. Mansukani completed a residency and fellowship in ophthalmology at the University of Pennsylvania School of Medicine and a fellowship in quality management and managed care at the Wharton School of the University of Pennsylvania. Dr. Mansukani is a graduate of the Managed Care Executive Program at the Kellogg School of Business and is board certified in medical management by the American College of Physician Executives.
高管简历
中英对照 | 中文 | 英文- Ron Williams
Ron Williams自2017年以来一直担任Agilon Health的董事兼董事会主席。Williams先生也是RW2Enterprises的董事长兼首席执行官，并担任CD&R的运营顾问。Williams先生是American Express Company公司、波音公司公司和强生公司公司的董事。Williams先生还于2011年5月至2017年10月担任Envision梦百合的董事会成员。Williams先生分别于2006年2月和2006年10月至2010年12月和2011年4月担任安泰保险金融集团的首席执行官和董事长。Williams先生还担任Conference Board的主席以及NAF和Peterson Institute for International Economics的董事。Williams先生在罗斯福大学（Roosevelt University）获得学士学位，并在麻省理工学院斯隆管理学院（MIT Sloan School of Management）获得管理学硕士学位。
Ron Williams has served as a director and chairman of the board of agilon health since 2017. Mr. Williams also is chairman and CEO of RW2 Enterprises and serves as an operating advisor to CD&R. Mr. Williams serves on the board of directors of American Express Company, The Boeing Company and Johnson & Johnson. Mr. Williams also served on the Board of Envision Healthcare from May 2011 to October 2017. Mr. Williams served as the CEO and Chairman of Aetna Inc. from February 2006 and October 2006 to December 2010 and April 2011 respectively. Mr. Williams also serves as Chairman of The Conference Board and a director of NAF and the Peterson Institute for International Economics. Mr. Williams received his B.A. from Roosevelt University and holds an M.S. in Management from MIT Sloan School of Management.- Ron Williams自2017年以来一直担任Agilon Health的董事兼董事会主席。Williams先生也是RW2Enterprises的董事长兼首席执行官，并担任CD&R的运营顾问。Williams先生是American Express Company公司、波音公司公司和强生公司公司的董事。Williams先生还于2011年5月至2017年10月担任Envision梦百合的董事会成员。Williams先生分别于2006年2月和2006年10月至2010年12月和2011年4月担任安泰保险金融集团的首席执行官和董事长。Williams先生还担任Conference Board的主席以及NAF和Peterson Institute for International Economics的董事。Williams先生在罗斯福大学（Roosevelt University）获得学士学位，并在麻省理工学院斯隆管理学院（MIT Sloan School of Management）获得管理学硕士学位。
- Ron Williams has served as a director and chairman of the board of agilon health since 2017. Mr. Williams also is chairman and CEO of RW2 Enterprises and serves as an operating advisor to CD&R. Mr. Williams serves on the board of directors of American Express Company, The Boeing Company and Johnson & Johnson. Mr. Williams also served on the Board of Envision Healthcare from May 2011 to October 2017. Mr. Williams served as the CEO and Chairman of Aetna Inc. from February 2006 and October 2006 to December 2010 and April 2011 respectively. Mr. Williams also serves as Chairman of The Conference Board and a director of NAF and the Peterson Institute for International Economics. Mr. Williams received his B.A. from Roosevelt University and holds an M.S. in Management from MIT Sloan School of Management.
- Ben Shaker
Ben Shaker自2020年9月起担任我们的首席市场官。Shaker先生于2017年1月加入Agilon Health，担任俄亥俄州市场总裁。Shaker先生于2013年12月至2017年1月担任Trinity Health旗下Mount Carmel Health Partners的Vice President兼首席运营官。Shaker先生在扬斯敦州立大学（Youngstown State University）获得学士学位，并持有俄亥俄州立大学（Ohio State University）的卫生管理硕士学位。
Ben Shaker has served as Chief Markets Officer since September 2020. Mr. Shaker joined agilon health as Ohio Market President in January 2017. Mr. Shaker served as Vice President and COO for Mount Carmel Health Partners, which is part of Trinity Health, from December 2013 to January 2017. Mr. Shaker received his B.A. from Youngstown State University and holds a Master's degree in Health Administration from The Ohio State University.- Ben Shaker自2020年9月起担任我们的首席市场官。Shaker先生于2017年1月加入Agilon Health，担任俄亥俄州市场总裁。Shaker先生于2013年12月至2017年1月担任Trinity Health旗下Mount Carmel Health Partners的Vice President兼首席运营官。Shaker先生在扬斯敦州立大学（Youngstown State University）获得学士学位，并持有俄亥俄州立大学（Ohio State University）的卫生管理硕士学位。
- Ben Shaker has served as Chief Markets Officer since September 2020. Mr. Shaker joined agilon health as Ohio Market President in January 2017. Mr. Shaker served as Vice President and COO for Mount Carmel Health Partners, which is part of Trinity Health, from December 2013 to January 2017. Mr. Shaker received his B.A. from Youngstown State University and holds a Master's degree in Health Administration from The Ohio State University.
- Girish Venkatachaliah
Girish Venkatachaliah自2021年1月起担任我们的首席技术官。Venkatachaliah先生于2020年7月至2021年1月担任Frazier梦百合Partners的增长收购团队的数据和人工智能合伙人。此前，Venkatachaliah先生于2019年9月至2020年4月担任Decision Resources Group的首席技术与产品官。Venkatachaliah先生还于2017年7月至2019年9月担任AthenaHealth数据战略，分析和人工智能/机器学习Vice President，领导战略，研究，产品管理和工程团队。任职AthenaHealth公司之前，Venkatachaliah先生曾担任IBM公司的多个执行职务，并在离职时担任产品开发公司的Vice President，负责数据和人工智能方面的云产品组合。Venkatachaliah先生在班加罗尔大学（Bangalore University）获得学士学位，在内华达大学拉斯维加斯分校（University of Nevada，Las Vegas）、圣克拉拉大学（Santa Clara University）以及加州大学伯克利分校（University of California，Berkeley）和哥伦比亚大学（Columbia University）联合获得硕士学位。
Girish Venkatachaliah has served as Chief Technology Officer since January 2021. Mr. Venkatachaliah served as a Partner, Data and Artificial Intelligence on the Growth Buyout team at Frazier Healthcare Partners from July 2020 to January 2021. Previously, Mr. Venkatachaliah served as the Chief Technology & Product Officer of Decision Resources Group from September 2019 to April 2020. Mr. Venkatachaliah also served as the Vice President of Data Strategy, Analytics, and Artificial Intelligence/Machine Learning at athenahealth from July 2017 to September 2019 where he led the strategy, research, product management and engineering teams. Prior to athenahealth, Mr. Venkatachaliah held several executive roles at IBM and was the Vice President of Product Development, responsible for a portfolio of cloud offerings in Data and Artificial Intelligence, at the time of his departure. Mr. Venkatachaliah received a Bachelor's degree from Bangalore University and Master's degrees from University of Nevada, Las Vegas, Santa Clara University and jointly from the University of California, Berkeley and Columbia University.- Girish Venkatachaliah自2021年1月起担任我们的首席技术官。Venkatachaliah先生于2020年7月至2021年1月担任Frazier梦百合Partners的增长收购团队的数据和人工智能合伙人。此前，Venkatachaliah先生于2019年9月至2020年4月担任Decision Resources Group的首席技术与产品官。Venkatachaliah先生还于2017年7月至2019年9月担任AthenaHealth数据战略，分析和人工智能/机器学习Vice President，领导战略，研究，产品管理和工程团队。任职AthenaHealth公司之前，Venkatachaliah先生曾担任IBM公司的多个执行职务，并在离职时担任产品开发公司的Vice President，负责数据和人工智能方面的云产品组合。Venkatachaliah先生在班加罗尔大学（Bangalore University）获得学士学位，在内华达大学拉斯维加斯分校（University of Nevada，Las Vegas）、圣克拉拉大学（Santa Clara University）以及加州大学伯克利分校（University of California，Berkeley）和哥伦比亚大学（Columbia University）联合获得硕士学位。
- Girish Venkatachaliah has served as Chief Technology Officer since January 2021. Mr. Venkatachaliah served as a Partner, Data and Artificial Intelligence on the Growth Buyout team at Frazier Healthcare Partners from July 2020 to January 2021. Previously, Mr. Venkatachaliah served as the Chief Technology & Product Officer of Decision Resources Group from September 2019 to April 2020. Mr. Venkatachaliah also served as the Vice President of Data Strategy, Analytics, and Artificial Intelligence/Machine Learning at athenahealth from July 2017 to September 2019 where he led the strategy, research, product management and engineering teams. Prior to athenahealth, Mr. Venkatachaliah held several executive roles at IBM and was the Vice President of Product Development, responsible for a portfolio of cloud offerings in Data and Artificial Intelligence, at the time of his departure. Mr. Venkatachaliah received a Bachelor's degree from Bangalore University and Master's degrees from University of Nevada, Las Vegas, Santa Clara University and jointly from the University of California, Berkeley and Columbia University.
- Timothy Gertsch
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Jeffrey A. Schwaneke
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Karthik Rao
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Denise Zamore
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Heidi Hittner
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介